Citigroup Inc. grew its holdings in INC Research Holdings, Inc. (NASDAQ:INCR) by 555.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,791 shares of the company’s stock after purchasing an additional 4,060 shares during the period. Citigroup Inc.’s holdings in INC Research Holdings were worth $281,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in INCR. UBS Asset Management Americas Inc. lifted its stake in shares of INC Research Holdings by 27.1% in the 1st quarter. UBS Asset Management Americas Inc. now owns 30,118 shares of the company’s stock valued at $1,381,000 after purchasing an additional 6,423 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new position in shares of INC Research Holdings in the 1st quarter valued at $164,000. Prudential Financial Inc. lifted its stake in shares of INC Research Holdings by 1,194.0% in the 1st quarter. Prudential Financial Inc. now owns 91,230 shares of the company’s stock valued at $4,183,000 after purchasing an additional 84,180 shares during the last quarter. American International Group Inc. lifted its stake in shares of INC Research Holdings by 5.3% in the 1st quarter. American International Group Inc. now owns 25,080 shares of the company’s stock valued at $1,150,000 after purchasing an additional 1,266 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in shares of INC Research Holdings by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 44,821 shares of the company’s stock valued at $2,055,000 after purchasing an additional 1,154 shares during the last quarter. 54.57% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have recently commented on INCR. Jefferies Group LLC lowered INC Research Holdings from a “buy” rating to a “hold” rating and upped their price target for the company from $62.00 to $64.00 in a research note on Thursday, June 29th. TheStreet lowered INC Research Holdings from a “b” rating to a “c” rating in a research note on Friday, July 28th. Zacks Investment Research raised INC Research Holdings from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research note on Wednesday, September 27th. Robert W. Baird reaffirmed a “buy” rating and issued a $67.00 price target on shares of INC Research Holdings in a research note on Monday, October 9th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $65.00 price target on shares of INC Research Holdings in a research note on Monday, August 7th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. INC Research Holdings presently has an average rating of “Buy” and a consensus price target of $64.22.

TRADEMARK VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/19/inc-research-holdings-inc-incr-stake-boosted-by-citigroup-inc.html.

In other news, CAO Christopher L. Gaenzle sold 4,682 shares of INC Research Holdings stock in a transaction on Monday, September 18th. The stock was sold at an average price of $54.56, for a total value of $255,449.92. Following the completion of the sale, the chief accounting officer now owns 60,579 shares of the company’s stock, valued at $3,305,190.24. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Alistair Macdonald sold 2,348 shares of INC Research Holdings stock in a transaction on Monday, September 18th. The shares were sold at an average price of $54.60, for a total value of $128,200.80. Following the completion of the sale, the chief executive officer now directly owns 99,453 shares of the company’s stock, valued at approximately $5,430,133.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 198,321 shares of company stock valued at $11,550,792. Company insiders own 0.24% of the company’s stock.

INC Research Holdings, Inc. (NASDAQ INCR) opened at 54.70 on Thursday. The company’s 50-day moving average price is $54.48 and its 200 day moving average price is $53.91. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of 33.52 and a beta of 1.34. INC Research Holdings, Inc. has a 1-year low of $40.65 and a 1-year high of $61.10.

INC Research Holdings (NASDAQ:INCR) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.64 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.64. The business had revenue of $258.10 million during the quarter, compared to the consensus estimate of $256.76 million. INC Research Holdings had a return on equity of 40.69% and a net margin of 5.69%. The business’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.61 earnings per share. On average, equities analysts expect that INC Research Holdings, Inc. will post $2.60 earnings per share for the current fiscal year.

INC Research Holdings Company Profile

INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

Institutional Ownership by Quarter for INC Research Holdings (NASDAQ:INCR)

Receive News & Stock Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related stocks with our FREE daily email newsletter.